母亲呼吸道合胞病毒疫苗接种与早产:犹他州全州回顾性队列研究
该研究为犹他州全州回顾性队列,纳入2023年9月至2024年2月分娩单胎且孕32 0/7至36 6/7周的个体,共24,213人中2,733人(11.3%)接种呼吸道合胞病毒(RSV)疫苗。接种与早产 odds 降低相关(接种组5.5% vs 未接种组6.8%,调整比值比0.80,95%CI 0.67-0.95),且未与不良出生结局相关。
要点
- 接种组早产率5.5%,未接种组6.8%,调整比值比0.80(95%CI 0.67-0.95)。
- RSV疫苗接种与妊娠期高血压疾病、低出生体重或胎儿/婴儿死亡无关。
- 研究结果支持该疫苗在孕期使用的安全性。
核心结论
- 母亲接种RSV疫苗与早产 odds 降低相关,且未与不良出生结局相关,支持该疫苗在孕期使用的安全性。
研究设计与样本
- 犹他州全州回顾性队列研究,纳入2023年9月至2024年2月分娩单胎且孕32 0/7至36 6/7周的个体,共24,213人,随访至分娩。
主要发现
- 24,213人中2,733人(11.3%)接种RSV疫苗。
- 接种组早产率5.5% vs 未接种组6.8%,调整比值比0.80(95%CI 0.67-0.95)。
- 接种RSV疫苗与妊娠期高血压疾病、低出生体重或胎儿/婴儿死亡等不良出生结局无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a statewide, retrospective cohort study to evaluate the association between maternal receipt of the respiratory syncytial virus (RSV) vaccine and preterm birth. All individuals who delivered a singleton neonate in Utah and were between 32 0/7 and 36 6/7 weeks of gestation from September 2023 to February 2024 were included and followed up until delivery. Overall, 2,733 of 24,213 individuals (11.3%) received the vaccine. Vaccine receipt was associated with lower odds of preterm birth (5.5% vaccinated group vs 6.8% unvaccinated group, adjusted odds ratio 0.80, 95% CI, 0.67-0.95). Receipt of the RSV vaccine was not associated with any adverse birth outcomes, including hypertensive disorders of pregnancy, low birth weight, or fetal or infant death. These findings support the safety of this vaccine in pregnancy, which is known to prevent neonatal severe lower respiratory tract disease.
引用
- Solsman AM, Metz TD, Benton J, et al. Maternal Respiratory Syncytial Virus Vaccination and Preterm Birth: A Utah Statewide Retrospective Cohort Study. Obstet Gynecol. 2025. PMID: 41289590. doi:10.1097/AOG.0000000000006130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。